Precigen Inc (PGEN)
1.40
+0.02
(+1.45%)
USD |
NASDAQ |
Apr 23, 16:00
1.40
0.00 (0.00%)
After-Hours: 20:00
Precigen Research and Development Expense (Quarterly): 12.99M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.99M |
| September 30, 2023 | 11.58M |
| June 30, 2023 | 11.87M |
| March 31, 2023 | 12.16M |
| December 31, 2022 | 10.79M |
| September 30, 2022 | 12.62M |
| June 30, 2022 | 11.95M |
| March 31, 2022 | 11.80M |
| December 31, 2021 | 12.18M |
| September 30, 2021 | 12.43M |
| June 30, 2021 | 13.18M |
| March 31, 2021 | 10.52M |
| December 31, 2020 | 10.67M |
| September 30, 2020 | 10.17M |
| June 30, 2020 | 9.474M |
| March 31, 2020 | 11.33M |
| December 31, 2019 | -41.42M |
| September 30, 2019 | 25.67M |
| June 30, 2019 | 28.24M |
| March 31, 2019 | 26.94M |
| December 31, 2018 | 208.94M |
| September 30, 2018 | 44.88M |
| June 30, 2018 | 42.05M |
| March 31, 2018 | 37.27M |
| Date | Value |
|---|---|
| December 31, 2017 | 4.513M |
| September 30, 2017 | 36.47M |
| June 30, 2017 | 34.01M |
| March 31, 2017 | 34.18M |
| December 31, 2016 | 28.87M |
| September 30, 2016 | 29.04M |
| June 30, 2016 | 28.38M |
| March 31, 2016 | 25.86M |
| December 31, 2015 | 26.20M |
| September 30, 2015 | 21.60M |
| June 30, 2015 | 20.38M |
| March 31, 2015 | 79.31M |
| December 31, 2014 | 17.64M |
| September 30, 2014 | 14.85M |
| June 30, 2014 | 14.43M |
| March 31, 2014 | 12.06M |
| December 31, 2013 | 12.55M |
| September 30, 2013 | 10.67M |
| June 30, 2013 | 13.51M |
| March 31, 2013 | 11.41M |
| December 31, 2012 | 13.05M |
| September 30, 2012 | 14.36M |
| June 30, 2012 | 17.64M |
| March 31, 2012 | 18.98M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-41.42M
Minimum
Dec 2019
28.24M
Maximum
Jun 2019
10.43M
Average
11.87M
Median
Jun 2023
Research and Development Expense (Quarterly) Benchmarks
| Cyclacel Pharmaceuticals Inc | 3.518M |
| HealthEquity Inc | 55.24M |
| Corvus Pharmaceuticals Inc | 3.999M |
| Oragenics Inc | 11.04M |
| MAIA Biotechnology Inc | 3.717M |